8 withdrawn. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Withdrawn 8 |
Follow Shock: new trials by email Literature Review of Shock trials Research Report on Shock
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Angiotensin II vs. Vasopressin in Septic Shock Angiotensin II, Vasopressin - Septic Shock | Phase 4 | Withdrawn | University of New Mexico | 2022-01-03 | 2024-03-15 | |
| High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19 Methylprednisolone, Tocilizumab - COVID-19 Virus Infection, Cytokine Storm | Phase 4 | Withdrawn | Marmara University | 2021-02-01 | 2021-11-24 | |
| Comparison of ARNI to Alternate Oral Vasodilator Therapies in Patients With Low Cardiac Output Sacubitril-Valsartan, Standard Oral Vasodilators - Cardiogenic Shock | Phase 4 | Withdrawn | The Cleveland Clinic | 2019-11-25 | 2020-10-05 | |
| Midodrine During Recovery From Septic Shock Midodrine, placebo - Hypotension, Shock, Septic | Phase 4 | Withdrawn | Northwell Health | 2017-08-01 | 2017-11-06 | |
| NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock Vasopressin, Norepinephrine - Shock, Septic | Phase 4 | Withdrawn | University of Arkansas | 2015-11-01 | 2017-11-29 | |
| Study Using Plasma for Patients Requiring Emergency Surgery Human Plasma - Hemorrhagic Shock, Blood Coagulation Disorders | Phase 4 | Withdrawn | Ottawa Hospital Research Institute | 2012-03-01 | 2023-05-08 | |
| Pre Hospital Evaluation of Video Laryngoscopy Classical intubation, GLIDESCOPE - Cardiac Arrest, Respiratory Distress Syndrome | Phase 4 | Withdrawn | Assistance Publique - Hôpitaux de Paris | 2011-06-01 | 2014-05-08 | |
| Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis Hydrocortisone, Fludrocortisone - Sepsis, Adrenal Insufficiency | Phase 4 | Withdrawn | CAMC Health System | 2006-09-01 | 2026-08-31 |
Shock, Septic (3) · Diabetes Insipidus (2) · Sepsis (2) · Adrenal Insufficiency (1) · Blood Coagulation Disorders (1) · COVID-19 (1) · Cytokine Release Syndrome (1) · Drug-Related Side Effects and Adverse Reactions (1) · Heart Arrest (1) · Hemorrhage (1) · Hemostatic Disorders (1) · Hypotension (1) · Respiratory Distress Syndrome (1) · Shock, Cardiogenic (1)
Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Infections (5) · Inflammation (5) · Cardiovascular Diseases (4) · Systemic Inflammatory Response Syndrome (4) · Endocrine System Diseases (3) · Vascular Diseases (3) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Heart Diseases (2) · Kidney Diseases (2) · Lung Diseases (2) · Male Urogenital Diseases (2)
Vasopressins (2) · Adrenal Cortex Hormones (1) · Angiotensin II (1) · Arginine Vasopressin (1) · Fludrocortisone (1) · Giapreza (1) · Hydrocortisone (1) · Methylprednisolone (1) · Midodrine (1) · Norepinephrine (1) · sacubitril and valsartan sodium hydrate drug combination (1) · tocilizumab (1)
Assistance Publique - Hôpitaux de Paris (1) · CAMC Health System (1) · Marmara University (1) · Northwell Health (1) · Ottawa Hospital Research Institute (1) · The Cleveland Clinic (1) · University of Arkansas (1) · University of New Mexico (1)
United States (3) · Canada (1)
David T Neilipovitz, MD (1) · Drayton Hammond, Pharm.D. (1) · Joao P Teixeira, MD (1) · John A Bethea, Pharm.D. (1) · Nathan D Nielsen, MD MSc (1) · Randall Starling, MD, MPH (1) · Ruslan Abdullayev (1)
PMID 10321661, PMID 10697064, PMID 10923728, PMID 12186604, PMID 29600824, PMID 3029157, PMID 3306374, PMID 4101232, PMID 6270176, PMID 6384785, PMID 7600840, PMID 7634816, PMID 7638758, PMID 8815944, PMID 8855809, PMID 9559600
UL1TR001449 (1)